- Home
- RMI vs MDXH Comparison
RMI vs MDXH Comparison
Compare RMI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMI
- MDXH
- Stock Information
- Founded
- RMI 2018
- MDXH 2003
- Country
- RMI United States
- MDXH Belgium
- Employees
- RMI N/A
- MDXH N/A
- Industry
- RMI Finance/Investors Services
- MDXH
- Sector
- RMI Finance
- MDXH
- Exchange
- RMI Nasdaq
- MDXH Nasdaq
- Market Cap
- RMI 91.2M
- MDXH 84.6M
- IPO Year
- RMI N/A
- MDXH 2021
- Fundamental
- Price
- RMI $14.32
- MDXH $1.99
- Analyst Decision
- RMI
- MDXH Buy
- Analyst Count
- RMI 0
- MDXH 1
- Target Price
- RMI N/A
- MDXH $6.00
- AVG Volume (30 Days)
- RMI 17.4K
- MDXH 72.1K
- Earning Date
- RMI 01-01-0001
- MDXH 05-14-2025
- Dividend Yield
- RMI 7.28%
- MDXH N/A
- EPS Growth
- RMI N/A
- MDXH N/A
- EPS
- RMI N/A
- MDXH N/A
- Revenue
- RMI N/A
- MDXH $94,507,000.00
- Revenue This Year
- RMI N/A
- MDXH $23.50
- Revenue Next Year
- RMI N/A
- MDXH $17.30
- P/E Ratio
- RMI N/A
- MDXH N/A
- Revenue Growth
- RMI N/A
- MDXH 25.46
- 52 Week Low
- RMI $13.05
- MDXH $1.35
- 52 Week High
- RMI $17.37
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- RMI 45.45
- MDXH 47.87
- Support Level
- RMI $14.26
- MDXH $1.96
- Resistance Level
- RMI $14.66
- MDXH $2.21
- Average True Range (ATR)
- RMI 0.23
- MDXH 0.12
- MACD
- RMI -0.01
- MDXH -0.03
- Stochastic Oscillator
- RMI 17.91
- MDXH 8.82
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.